前沿:肿瘤专科护士能开哪些药?——专家共识

2018-03-29 佚名 中护在线订阅号

目前,国外已经有22个国家的护士具有一定范围的处方权,在我国,安徽省成为第一个具有护士处方权的省份。但是目前给护士哪些药物的处方权已成为实现护士处方权的瓶颈之一。癌症专科护士有哪些处方权呢?国内专家就此给出了建议。慢性病症状管理7项特定情况癌性疼痛(延迟处方前提下)独立处方:阿司匹林、布洛芬、布洛芬缓释片协议处方:布桂嗪注射液、盐酸曲马多注射液、吗啡片、吗啡缓释片、吗啡注射液、芬太尼贴剂独立处方/

目前,国外已经有22个国家的护士具有一定范围的处方权,在我国,安徽省成为第一个具有护士处方权的省份。但是目前给护士哪些药物的处方权已成为实现护士处方权的瓶颈之一。癌症专科护士有哪些处方权呢?国内专家就此给出了建议。

慢性病症状管理7项特定情况

癌性疼痛

(延迟处方前提下)

独立处方:阿司匹林、布洛芬、布洛芬缓释片

协议处方:布桂嗪注射液、盐酸曲马多注射液、吗啡片、吗啡缓释片、吗啡注射液、芬太尼贴剂

独立处方/协议处方:氨酚待因、氯芬待因、盐酸布桂嗪片、盐酸曲马多片

呕吐

(延长处方前提下)

独立处方:多潘立酮、甲氧氯普胺片、盐酸甲氧氯普胺注射液

协议处方:苯海拉明、奥美拉唑、西咪替丁、司琼类止吐药

便秘

独立处方:开塞露、甘油、液状石蜡、酚酞片、番泻叶、麻仁丸、麻仁胶囊

腹泻

独立处方:双歧杆菌、地芬诺酯

协议处方:洛哌丁胺

独立处方/协议处方:蒙脱石散、口服补液盐

癌性发热

独立处方:萘普生片、吲哚美辛片、吲哚美辛栓、安痛定注射液、柴胡注射液

协议处方:地塞米松注射液

口腔感染

独立处方:氯己定、氯化钠溶液、甲硝唑溶液、过氧化氢溶液、碳酸氢钠溶液

协议处方:酮康唑、氟康唑、制霉菌素

静脉炎

独立处方:喜辽妥、硫酸镁、金黄散

肿瘤急症5项特定情况

化疗药物过敏

协议处方:地塞米松注射液、肾上腺素注射液

独立处方/协议处方:盐酸苯海拉明注射液

急性大咯血

独立处方:酚磺乙胺、氨甲苯酸

协议处方:巴曲酶、垂体后叶素

急性上消化道大出血

独立处方:奥美拉唑

协议处方:生长抑素

独立处方/协议处方:巴曲酶

失血性休克

独立处方:氯化钠、格林液

独立处方/协议处方:右旋糖酐

脑疝

独立处方/协议处方:甘露醇

9项实验室检查

独立处方:血常规、血生化、凝血检查、血培养、痰培养、尿培养、心电图、粪便检查

独立处方/协议处方:肿瘤标志物

文章来源:

新时代护士处方权内容专家共识.护理研究.2018,32(1):1-5.

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1845097, encodeId=a90a184509ebd, content=<a href='/topic/show?id=5d2f206482e' target=_blank style='color:#2F92EE;'>#专家共识#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=20648, encryptionId=5d2f206482e, topicName=专家共识)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=568152, createdName=snowpeakxu, createdTime=Mon May 07 09:39:00 CST 2018, time=2018-05-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1715349, encodeId=dff11e15349ce, content=<a href='/topic/show?id=235220e0106' target=_blank style='color:#2F92EE;'>#专科#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=20701, encryptionId=235220e0106, topicName=专科)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=894231925290, createdName=12498ebem29暂无昵称, createdTime=Tue Dec 04 15:39:00 CST 2018, time=2018-12-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=300985, encodeId=e5d830098564, content=希望政策快些成熟, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/12/25/1e747f2d6cd0aa12909188d5d28b97d6.jpg, createdBy=41712232022, createdName=zehuiwang, createdTime=Fri Mar 30 00:24:32 CST 2018, time=2018-03-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=300941, encodeId=801730094123, content=不错的文章值得拥有, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=eff51996281, createdName=1e1b8538m79(暂无匿称), createdTime=Thu Mar 29 22:15:01 CST 2018, time=2018-03-29, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1845097, encodeId=a90a184509ebd, content=<a href='/topic/show?id=5d2f206482e' target=_blank style='color:#2F92EE;'>#专家共识#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=20648, encryptionId=5d2f206482e, topicName=专家共识)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=568152, createdName=snowpeakxu, createdTime=Mon May 07 09:39:00 CST 2018, time=2018-05-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1715349, encodeId=dff11e15349ce, content=<a href='/topic/show?id=235220e0106' target=_blank style='color:#2F92EE;'>#专科#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=20701, encryptionId=235220e0106, topicName=专科)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=894231925290, createdName=12498ebem29暂无昵称, createdTime=Tue Dec 04 15:39:00 CST 2018, time=2018-12-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=300985, encodeId=e5d830098564, content=希望政策快些成熟, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/12/25/1e747f2d6cd0aa12909188d5d28b97d6.jpg, createdBy=41712232022, createdName=zehuiwang, createdTime=Fri Mar 30 00:24:32 CST 2018, time=2018-03-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=300941, encodeId=801730094123, content=不错的文章值得拥有, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=eff51996281, createdName=1e1b8538m79(暂无匿称), createdTime=Thu Mar 29 22:15:01 CST 2018, time=2018-03-29, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1845097, encodeId=a90a184509ebd, content=<a href='/topic/show?id=5d2f206482e' target=_blank style='color:#2F92EE;'>#专家共识#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=20648, encryptionId=5d2f206482e, topicName=专家共识)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=568152, createdName=snowpeakxu, createdTime=Mon May 07 09:39:00 CST 2018, time=2018-05-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1715349, encodeId=dff11e15349ce, content=<a href='/topic/show?id=235220e0106' target=_blank style='color:#2F92EE;'>#专科#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=20701, encryptionId=235220e0106, topicName=专科)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=894231925290, createdName=12498ebem29暂无昵称, createdTime=Tue Dec 04 15:39:00 CST 2018, time=2018-12-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=300985, encodeId=e5d830098564, content=希望政策快些成熟, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/12/25/1e747f2d6cd0aa12909188d5d28b97d6.jpg, createdBy=41712232022, createdName=zehuiwang, createdTime=Fri Mar 30 00:24:32 CST 2018, time=2018-03-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=300941, encodeId=801730094123, content=不错的文章值得拥有, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=eff51996281, createdName=1e1b8538m79(暂无匿称), createdTime=Thu Mar 29 22:15:01 CST 2018, time=2018-03-29, status=1, ipAttribution=)]
    2018-03-30 zehuiwang

    希望政策快些成熟

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1845097, encodeId=a90a184509ebd, content=<a href='/topic/show?id=5d2f206482e' target=_blank style='color:#2F92EE;'>#专家共识#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=20648, encryptionId=5d2f206482e, topicName=专家共识)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=568152, createdName=snowpeakxu, createdTime=Mon May 07 09:39:00 CST 2018, time=2018-05-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1715349, encodeId=dff11e15349ce, content=<a href='/topic/show?id=235220e0106' target=_blank style='color:#2F92EE;'>#专科#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=20701, encryptionId=235220e0106, topicName=专科)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=894231925290, createdName=12498ebem29暂无昵称, createdTime=Tue Dec 04 15:39:00 CST 2018, time=2018-12-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=300985, encodeId=e5d830098564, content=希望政策快些成熟, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/12/25/1e747f2d6cd0aa12909188d5d28b97d6.jpg, createdBy=41712232022, createdName=zehuiwang, createdTime=Fri Mar 30 00:24:32 CST 2018, time=2018-03-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=300941, encodeId=801730094123, content=不错的文章值得拥有, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=eff51996281, createdName=1e1b8538m79(暂无匿称), createdTime=Thu Mar 29 22:15:01 CST 2018, time=2018-03-29, status=1, ipAttribution=)]
    2018-03-29 1e1b8538m79(暂无匿称)

    不错的文章值得拥有

    0

相关资讯

AUTOPHAGY:自噬抑制治疗耐药肿瘤

宏自噬/自噬已经被鉴定为诱导代谢应激的抗癌药物治疗的抗性机制。一些特定的肿瘤,包括KRAS突变NSCLCs的一个亚群,已被证明对自噬“上瘾”,并且可能对自噬的抑制敏感。

中医药专家:肿瘤患者选择中草药治疗应避免两大误区

近年来,不少肿瘤患者在化疗、放疗之外,还选择了中草药治疗方式。一些中医药专家指出,目前,肿瘤患者选择中草药治疗应避免两大误区。

肿瘤患者只有手术管用,化疗放疗只会让情况更差?

肿瘤,尤其是恶性肿瘤,让所有人都提心吊胆。虽然,现代医学发展飞速,但还未能攻克“恶性肿瘤”这道坎。真假难辨的“科普”,又让不少患者走了弯路。就说化疗,大家听到这词,就很容易想到呕吐、脱发、精神不振。的确,化疗药物或多或少都会引起一些身体的不良反应。即便如今药物不断改良、技术不断改善的情况下,化疗的副作用依旧不能减少到没有。但是,这并不代表化疗就是无用功,只会让身体变更差。复旦大学附属肿瘤医院肿瘤

Cancer Cell:高通量肿瘤功能基因组注释与分析

人类在征服疾病的进程中虽然曲折前行,但是收获匪浅。基于癌症的诊断与治疗,已经由传统的化疗、放疗逐渐发展为靶向疗法、免疫疗法,并继续走向组合疗法和精准个体医疗。癌症,和其他很多复杂综合症一样,在病人群体中存在着极大的基因型(genotype)差异,导致很难用单一的药物控制症状。随着新一代测序技术的建立和测序成本的大幅度降低,越来越多的病人可以完成全基因组测序(whole-genome sequenc

STM:新型癌症免疫疗法一次注射消灭几乎所有肿瘤

近日,一组来自斯坦福大学的研究人员在《科学》杂志旗下著名学术期刊《科学-转化医学》发表一篇重磅研究文章,研究者们将微量两种免疫刺激剂直接注射到90只小鼠的实体瘤中,有效的消除了87只小鼠体内所有的癌症痕迹,为肿瘤免疫治疗带来了新的动力。

EAU18 ︱魏强教授:人工智能在泌尿系肿瘤诊疗中的应用进展

本届EAU大会首日,四川大学华西医院泌尿外科魏强教授团队的“利用机器学习模型预测及改善前列腺癌根治术后患者控尿功能”成果发言受到了与会学者高度关注。由于根治手术技术的日臻完善以及局限性前列腺癌具有较好的生存预后,患者术后的功能学结局(尿控、尿垫使用情况)及生活质量受到更多的关注。然而传统回归模型只能针对全人群绘制出统一的预测方程,很难满足精准医学及人民生活水平快速提升背景下医生临床决策及患者追